Sinovac Biotech (SVA) reported $386M in revenue for fiscal 2025, +6.8% year on year. That ranks #2369 by revenue among 2853 SEC filers and #231 in Healthcare. It posted a net loss of −$199M for the same year. Revenue has grown 20.4% a year on average since 2016 ($72.4M then). The fiscal 2025 balance sheet shows $8.5B in total assets, $488M in cash and $495M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $386M | +6.8% | FY20252025-12-31 |
| Gross profitGrossProfit | $262M | +18.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$490M | +$15.4M | FY20252025-12-31 |
| Net incomeProfitLoss | −$199M | −$239M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$512M | −$455M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $48.9M | −49.0% | FY20252025-12-31 |
| Total assetsAssets | $8.5B | −30.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $4.4B | −46.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $488M | +45.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $495M | +31.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Profile
- Legal name
- Sinovac Biotech LTD
- Ticker
- SVA
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001084201
Filings
- 20-FJun 5, 2026Open filing →
- 20-FApr 30, 2026Open filing →
- 20-FApr 29, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| ArdelyxARDX | $407M | −$62.0M |
| Immunocore HoldingsIMCR | $400M | −$35.5M |
| Krystal BiotechKRYS | $389M | $205M |
| Sinovac BiotechSVA | $386M | −$199M |
| Sonida Senior LivingSNDA | $381M | −$72.5M |
| CaredxCDNA | $380M | −$21.4M |
| Twist BioscienceTWST | $377M | −$77.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Sinovac Biotech — Key figures |url=https://companiesranked.com/en/company/sinovac-biotech |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Sinovac Biotech — Key figures. CompaniesRanked. https://companiesranked.com/en/company/sinovac-biotechBibTeX
@misc{companiesranked-en-company-sinovac-biotech-2026,
author = {{CompaniesRanked}},
title = {{Sinovac Biotech — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/sinovac-biotech}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-258534 · June 5, 2026
{{cite web |title=Sinovac Biotech — Key figures — 20-F (0001193125-26-258534) |url=https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-06-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.